tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2021 Dec 14;101568.
doi: 10.1016/j.rmcr.2021.101568. Online ahead of print.
Acute liver failure after vaccination against of COVID-19; a case report and review literature
Masoudreza Sohrabi[SUP] 1 [/SUP], Elham Sobhe Rakhshankhah[SUP] 1 [/SUP], Hosein Ziaei[SUP] 1 [/SUP], Manizhe Ataee Kachuee[SUP] 2 [/SUP], Farhad Zamani[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Vaccination against COVID-19 remains as a main root of COVID-19 prevention. Few vaccines have been launched for this purpose recently with different side effects. Thrombotic events have been reported as a rare side effect after ChAdox1nCOV-19 vaccination that may cause death of recipient.
Case presentation: We report a case of hepatic artery occlusion after the first dose vaccination by ChAdOx1nCov-19.The patient was a health care worker, aged 34-year old. Past medical history was unremarkable and had not used heparin. Over the next couple of days after the vaccination, he reported headache, nausea, and dizziness as well as abdominal pain. His general status and the laboratories studies deteriorate quickly by increasing liver enzymes and severe coagulopathy. Clinically he had presented acute hepatic failure. He had been received blood products, prednisolone pulse along with broad antibiotics without benefit. He died on the sixth day.
Conclusions: Thrombotic events after vaccination is very rare but can develop in main arteries with lethal outcome. This event may mimic autoimmune thrombosis clinically.
Keywords: Adverse events, AEs; Amino acid cleaving enzyme, FURIN; COVID-19; Complete Blood count, CBC; Coronavirus disease 2019, COVID-19; Embolism; European Medicines Agency, EMA; Heparin-induced thrombocytopenia, HIT; Intensive-care unit, ICU; Liver; Partial thrombin time, PTT; Platelet factor 4, PF4; Prothrombin time, PT; Trans membrane serine protease 2, TMPRSS2; UK Medicines and other Health products Regulatory Agency, MHRA; Vaccination.
. 2021 Dec 14;101568.
doi: 10.1016/j.rmcr.2021.101568. Online ahead of print.
Acute liver failure after vaccination against of COVID-19; a case report and review literature
Masoudreza Sohrabi[SUP] 1 [/SUP], Elham Sobhe Rakhshankhah[SUP] 1 [/SUP], Hosein Ziaei[SUP] 1 [/SUP], Manizhe Ataee Kachuee[SUP] 2 [/SUP], Farhad Zamani[SUP] 1 [/SUP]
Affiliations
- PMID: 34926142
- PMCID: PMC8668601
- DOI: 10.1016/j.rmcr.2021.101568
Abstract
Background: Vaccination against COVID-19 remains as a main root of COVID-19 prevention. Few vaccines have been launched for this purpose recently with different side effects. Thrombotic events have been reported as a rare side effect after ChAdox1nCOV-19 vaccination that may cause death of recipient.
Case presentation: We report a case of hepatic artery occlusion after the first dose vaccination by ChAdOx1nCov-19.The patient was a health care worker, aged 34-year old. Past medical history was unremarkable and had not used heparin. Over the next couple of days after the vaccination, he reported headache, nausea, and dizziness as well as abdominal pain. His general status and the laboratories studies deteriorate quickly by increasing liver enzymes and severe coagulopathy. Clinically he had presented acute hepatic failure. He had been received blood products, prednisolone pulse along with broad antibiotics without benefit. He died on the sixth day.
Conclusions: Thrombotic events after vaccination is very rare but can develop in main arteries with lethal outcome. This event may mimic autoimmune thrombosis clinically.
Keywords: Adverse events, AEs; Amino acid cleaving enzyme, FURIN; COVID-19; Complete Blood count, CBC; Coronavirus disease 2019, COVID-19; Embolism; European Medicines Agency, EMA; Heparin-induced thrombocytopenia, HIT; Intensive-care unit, ICU; Liver; Partial thrombin time, PTT; Platelet factor 4, PF4; Prothrombin time, PT; Trans membrane serine protease 2, TMPRSS2; UK Medicines and other Health products Regulatory Agency, MHRA; Vaccination.